Emerging Company Profile
Atalanta’s next-gen RNAi branches deeper into brain, hooks Biogen and Genentech
Emerging Company Profile: Newco launches with UMass Med’s branched siRNA tech, $110M in cash
Atalanta Therapeutics launches with UMass Medical’s branched siRNA technology and $110 million in cash from investor F-Prime and partners Biogen and Genentech.
Jan 12, 2021 | 2:05 AM GMT
A rush of interest following the publication of Atalanta’s